213 related articles for article (PubMed ID: 24712003)
1. [Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
Borbély K; Németh Z; Kásler M
Magy Onkol; 2014 Mar; 58(1):24-31. PubMed ID: 24712003
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
3. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
6. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
7. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
10. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
Kostakoglu L; Hardoff R; Mirtcheva R; Goldsmith SJ
Radiographics; 2004; 24(5):1411-31. PubMed ID: 15371617
[TBL] [Abstract][Full Text] [Related]
11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
12. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
13. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
14. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
16. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma.
Leijte JA; Graafland NM; Valdés Olmos RA; van Boven HH; Hoefnagel CA; Horenblas S
BJU Int; 2009 Sep; 104(5):640-4. PubMed ID: 19281465
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT in pediatric solid tumors.
Franzius C
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):401-10. PubMed ID: 20823808
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
20. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
[Next] [New Search]
